Arlene Naranjo

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

Thomas F. Eleveld, Derek A. Oldridge, Virginie Bernard et al. · Nature Genetics · 2015 · 543 citations

Receptor Tyrosine Kinase, Pathology, Neuroblasts +5

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Meredith S. Irwin, Arlene Naranjo, Fan F. Zhang et al. · Journal of Clinical Oncology · 2021 · 439 citations · Full text

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

Julie R. Park, Susan G. Kreissman, Wendy B. London et al. · JAMA · 2019 · 336 citations · Full text

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 268 citations · Full text

Cog Anbl1221, Neuro-oncology, Glioma +4

Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

Gregory A. Yanik, Marguerite T. Parisi, Barry L. Shulkin et al. · Journal of Nuclear Medicine · 2013 · 203 citations · Full text